Only AI-treated patients with HER2- tumours, paired baseline and surgery Ki67 available, and baseline Ki67 immunohistochemistry (IHC) > 10% (to minimise imprecision in proportional Ki67 falls) were included for selection. The gene discussed is MKI67; the disease is neoplasm.